img

Global Antiretroviral Agent Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antiretroviral Agent Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The clinical use of antiretroviral agents involves a pathogenesis-based, combination treatment approach. Increase in the number of chronic diseases, HIV infections will lead to more medicinal development. The surge for anti-resistant medicines has been in demand. In addition as monoclonal antibodies demand increases, the growth for the antiretroviral (ARV) agents market will spike its rate, demand in personalized medicines has increased bio production, accelerating antiretroviral (ARV) demand.
The global Antiretroviral Agent market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Antiretroviral Agent is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Antiretroviral Agent is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Antiretroviral Agent is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Antiretroviral Agent include ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Bristol-Myers Squibb, Janssen Pharmaceuticals, Pfizer, Boehringer Ingelheim and AbbVie, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Antiretroviral Agent, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Antiretroviral Agent by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Antiretroviral Agent market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Antiretroviral Agent market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


ViiV Healthcare
Gilead Sciences
GlaxoSmithKline
Merck Sharp and Dohme
Bristol-Myers Squibb
Janssen Pharmaceuticals
Pfizer
Boehringer Ingelheim
AbbVie
Genentech
Mylan
By Type
Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors—CCR5 Co-Receptor Antagonist
Fusion Inhibitors
Others
By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Antiretroviral Agent in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Antiretroviral Agent manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiretroviral Agent sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Antiretroviral Agent Definition
1.2 Market by Type
1.2.1 Global Antiretroviral Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Protease Inhibitors
1.2.4 HIV Integrase Strand Transfer Inhibitors
1.2.5 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.6 Entry Inhibitors—CCR5 Co-Receptor Antagonist
1.2.7 Fusion Inhibitors
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Antiretroviral Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Antiretroviral Agent Sales
2.1 Global Antiretroviral Agent Revenue Estimates and Forecasts 2018-2034
2.2 Global Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Antiretroviral Agent Revenue by Region
2.3.1 Global Antiretroviral Agent Revenue by Region (2018-2024)
2.3.2 Global Antiretroviral Agent Revenue by Region (2024-2034)
2.4 Global Antiretroviral Agent Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Antiretroviral Agent Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Antiretroviral Agent Sales Quantity by Region
2.6.1 Global Antiretroviral Agent Sales Quantity by Region (2018-2024)
2.6.2 Global Antiretroviral Agent Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Antiretroviral Agent Sales Quantity by Manufacturers
3.1.1 Global Antiretroviral Agent Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Antiretroviral Agent Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Antiretroviral Agent Sales in 2022
3.2 Global Antiretroviral Agent Revenue by Manufacturers
3.2.1 Global Antiretroviral Agent Revenue by Manufacturers (2018-2024)
3.2.2 Global Antiretroviral Agent Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antiretroviral Agent Revenue in 2022
3.3 Global Antiretroviral Agent Sales Price by Manufacturers
3.4 Global Key Players of Antiretroviral Agent, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antiretroviral Agent, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antiretroviral Agent, Product Offered and Application
3.8 Global Key Manufacturers of Antiretroviral Agent, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Antiretroviral Agent Sales Quantity by Type
4.1.1 Global Antiretroviral Agent Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Antiretroviral Agent Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
4.2 Global Antiretroviral Agent Revenue by Type
4.2.1 Global Antiretroviral Agent Historical Revenue by Type (2018-2024)
4.2.2 Global Antiretroviral Agent Forecasted Revenue by Type (2024-2034)
4.2.3 Global Antiretroviral Agent Revenue Market Share by Type (2018-2034)
4.3 Global Antiretroviral Agent Price by Type
4.3.1 Global Antiretroviral Agent Price by Type (2018-2024)
4.3.2 Global Antiretroviral Agent Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Antiretroviral Agent Sales Quantity by Application
5.1.1 Global Antiretroviral Agent Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Antiretroviral Agent Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
5.2 Global Antiretroviral Agent Revenue by Application
5.2.1 Global Antiretroviral Agent Historical Revenue by Application (2018-2024)
5.2.2 Global Antiretroviral Agent Forecasted Revenue by Application (2024-2034)
5.2.3 Global Antiretroviral Agent Revenue Market Share by Application (2018-2034)
5.3 Global Antiretroviral Agent Price by Application
5.3.1 Global Antiretroviral Agent Price by Application (2018-2024)
5.3.2 Global Antiretroviral Agent Price Forecast by Application (2024-2034)
6 North America
6.1 North America Antiretroviral Agent Sales by Company
6.1.1 North America Antiretroviral Agent Revenue by Company (2018-2024)
6.1.2 North America Antiretroviral Agent Sales Quantity by Company (2018-2024)
6.2 North America Antiretroviral Agent Market Size by Type
6.2.1 North America Antiretroviral Agent Sales Quantity by Type (2018-2034)
6.2.2 North America Antiretroviral Agent Revenue by Type (2018-2034)
6.3 North America Antiretroviral Agent Market Size by Application
6.3.1 North America Antiretroviral Agent Sales Quantity by Application (2018-2034)
6.3.2 North America Antiretroviral Agent Revenue by Application (2018-2034)
6.4 North America Antiretroviral Agent Market Size by Country
6.4.1 North America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Antiretroviral Agent Revenue by Country (2018-2034)
6.4.3 North America Antiretroviral Agent Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Antiretroviral Agent Sales by Company
7.1.1 Europe Antiretroviral Agent Sales Quantity by Company (2018-2024)
7.1.2 Europe Antiretroviral Agent Revenue by Company (2018-2024)
7.2 Europe Antiretroviral Agent Market Size by Type
7.2.1 Europe Antiretroviral Agent Sales Quantity by Type (2018-2034)
7.2.2 Europe Antiretroviral Agent Revenue by Type (2018-2034)
7.3 Europe Antiretroviral Agent Market Size by Application
7.3.1 Europe Antiretroviral Agent Sales Quantity by Application (2018-2034)
7.3.2 Europe Antiretroviral Agent Revenue by Application (2018-2034)
7.4 Europe Antiretroviral Agent Market Size by Country
7.4.1 Europe Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Antiretroviral Agent Revenue by Country (2018-2034)
7.4.3 Europe Antiretroviral Agent Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Antiretroviral Agent Sales by Company
8.1.1 China Antiretroviral Agent Sales Quantity by Company (2018-2024)
8.1.2 China Antiretroviral Agent Revenue by Company (2018-2024)
8.2 China Antiretroviral Agent Market Size by Type
8.2.1 China Antiretroviral Agent Sales Quantity by Type (2018-2034)
8.2.2 China Antiretroviral Agent Revenue by Type (2018-2034)
8.3 China Antiretroviral Agent Market Size by Application
8.3.1 China Antiretroviral Agent Sales Quantity by Application (2018-2034)
8.3.2 China Antiretroviral Agent Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Antiretroviral Agent Sales by Company
9.1.1 APAC Antiretroviral Agent Sales Quantity by Company (2018-2024)
9.1.2 APAC Antiretroviral Agent Revenue by Company (2018-2024)
9.2 APAC Antiretroviral Agent Market Size by Type
9.2.1 APAC Antiretroviral Agent Sales Quantity by Type (2018-2034)
9.2.2 APAC Antiretroviral Agent Revenue by Type (2018-2034)
9.3 APAC Antiretroviral Agent Market Size by Application
9.3.1 APAC Antiretroviral Agent Sales Quantity by Application (2018-2034)
9.3.2 APAC Antiretroviral Agent Revenue by Application (2018-2034)
9.4 APAC Antiretroviral Agent Market Size by Region
9.4.1 APAC Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Antiretroviral Agent Revenue by Region (2018-2034)
9.4.3 APAC Antiretroviral Agent Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antiretroviral Agent Sales by Company
10.1.1 Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Antiretroviral Agent Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Antiretroviral Agent Market Size by Type
10.2.1 Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Antiretroviral Agent Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Antiretroviral Agent Market Size by Application
10.3.1 Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Antiretroviral Agent Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Antiretroviral Agent Market Size by Country
10.4.1 Middle East, Africa and Latin America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Antiretroviral Agent Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Information
11.1.2 ViiV Healthcare Overview
11.1.3 ViiV Healthcare Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 ViiV Healthcare Antiretroviral Agent Products and Services
11.1.5 ViiV Healthcare Antiretroviral Agent SWOT Analysis
11.1.6 ViiV Healthcare Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Information
11.2.2 Gilead Sciences Overview
11.2.3 Gilead Sciences Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Gilead Sciences Antiretroviral Agent Products and Services
11.2.5 Gilead Sciences Antiretroviral Agent SWOT Analysis
11.2.6 Gilead Sciences Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 GlaxoSmithKline Antiretroviral Agent Products and Services
11.3.5 GlaxoSmithKline Antiretroviral Agent SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Merck Sharp and Dohme
11.4.1 Merck Sharp and Dohme Company Information
11.4.2 Merck Sharp and Dohme Overview
11.4.3 Merck Sharp and Dohme Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Merck Sharp and Dohme Antiretroviral Agent Products and Services
11.4.5 Merck Sharp and Dohme Antiretroviral Agent SWOT Analysis
11.4.6 Merck Sharp and Dohme Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Information
11.5.2 Bristol-Myers Squibb Overview
11.5.3 Bristol-Myers Squibb Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Bristol-Myers Squibb Antiretroviral Agent Products and Services
11.5.5 Bristol-Myers Squibb Antiretroviral Agent SWOT Analysis
11.5.6 Bristol-Myers Squibb Recent Developments
11.6 Janssen Pharmaceuticals
11.6.1 Janssen Pharmaceuticals Company Information
11.6.2 Janssen Pharmaceuticals Overview
11.6.3 Janssen Pharmaceuticals Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Janssen Pharmaceuticals Antiretroviral Agent Products and Services
11.6.5 Janssen Pharmaceuticals Antiretroviral Agent SWOT Analysis
11.6.6 Janssen Pharmaceuticals Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Pfizer Antiretroviral Agent Products and Services
11.7.5 Pfizer Antiretroviral Agent SWOT Analysis
11.7.6 Pfizer Recent Developments
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Information
11.8.2 Boehringer Ingelheim Overview
11.8.3 Boehringer Ingelheim Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Boehringer Ingelheim Antiretroviral Agent Products and Services
11.8.5 Boehringer Ingelheim Antiretroviral Agent SWOT Analysis
11.8.6 Boehringer Ingelheim Recent Developments
11.9 AbbVie
11.9.1 AbbVie Company Information
11.9.2 AbbVie Overview
11.9.3 AbbVie Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 AbbVie Antiretroviral Agent Products and Services
11.9.5 AbbVie Antiretroviral Agent SWOT Analysis
11.9.6 AbbVie Recent Developments
11.10 Genentech
11.10.1 Genentech Company Information
11.10.2 Genentech Overview
11.10.3 Genentech Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Genentech Antiretroviral Agent Products and Services
11.10.5 Genentech Antiretroviral Agent SWOT Analysis
11.10.6 Genentech Recent Developments
11.11 Mylan
11.11.1 Mylan Company Information
11.11.2 Mylan Overview
11.11.3 Mylan Antiretroviral Agent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Mylan Antiretroviral Agent Products and Services
11.11.5 Mylan Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antiretroviral Agent Value Chain Analysis
12.2 Antiretroviral Agent Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antiretroviral Agent Production Mode & Process
12.4 Antiretroviral Agent Sales and Marketing
12.4.1 Antiretroviral Agent Sales Channels
12.4.2 Antiretroviral Agent Distributors
12.5 Antiretroviral Agent Customers
13 Market Dynamics
13.1 Antiretroviral Agent Industry Trends
13.2 Antiretroviral Agent Market Drivers
13.3 Antiretroviral Agent Market Challenges
13.4 Antiretroviral Agent Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antiretroviral Agent Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Nucleoside Reverse Transcriptase Inhibitors
Table 3. Major Manufacturers of Protease Inhibitors
Table 4. Major Manufacturers of HIV Integrase Strand Transfer Inhibitors
Table 5. Major Manufacturers of Non-Nucleoside Reverse Transcriptase Inhibitors
Table 6. Major Manufacturers of Entry Inhibitors—CCR5 Co-Receptor Antagonist
Table 7. Major Manufacturers of Fusion Inhibitors
Table 8. Major Manufacturers of Others
Table 9. Global Antiretroviral Agent Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 11. Global Antiretroviral Agent Revenue by Region (2018-2024) & (US$ Million)
Table 12. Global Antiretroviral Agent Revenue Market Share by Region (2018-2024)
Table 13. Global Antiretroviral Agent Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global Antiretroviral Agent Revenue Market Share by Region (2024-2034)
Table 15. Global Antiretroviral Agent Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 16. Global Antiretroviral Agent Sales by Region (2018-2024) & (K Units)
Table 17. Global Antiretroviral Agent Sales Market Share by Region (2018-2024)
Table 18. Global Antiretroviral Agent Sales by Region (2024-2034) & (K Units)
Table 19. Global Antiretroviral Agent Sales Market Share by Region (2024-2034)
Table 20. Global Antiretroviral Agent Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 21. Global Antiretroviral Agent Sales Quantity Share by Manufacturers (2018-2024)
Table 22. Global Antiretroviral Agent Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 23. Global Antiretroviral Agent Revenue Share by Manufacturers (2018-2024)
Table 24. Global Antiretroviral Agent Price by Manufacturers 2018-2024 (US$/Unit)
Table 25. Global Key Players of Antiretroviral Agent, Industry Ranking, 2021 VS 2022
Table 26. Global Antiretroviral Agent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Antiretroviral Agent by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antiretroviral Agent as of 2022)
Table 28. Global Key Manufacturers of Antiretroviral Agent, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of Antiretroviral Agent, Product Offered and Application
Table 30. Global Key Manufacturers of Antiretroviral Agent, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 33. Global Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 34. Global Antiretroviral Agent Sales Quantity Share by Type (2018-2024)
Table 35. Global Antiretroviral Agent Sales Quantity Share by Type (2024-2034)
Table 36. Global Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 37. Global Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global Antiretroviral Agent Revenue Share by Type (2018-2024)
Table 39. Global Antiretroviral Agent Revenue Share by Type (2024-2034)
Table 40. Antiretroviral Agent Price by Type (2018-2024) & (US$/Unit)
Table 41. Global Antiretroviral Agent Price Forecast by Type (2024-2034) & (US$/Unit)
Table 42. Global Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 43. Global Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 44. Global Antiretroviral Agent Sales Quantity Share by Application (2018-2024)
Table 45. Global Antiretroviral Agent Sales Quantity Share by Application (2024-2034)
Table 46. Global Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 47. Global Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global Antiretroviral Agent Revenue Share by Application (2018-2024)
Table 49. Global Antiretroviral Agent Revenue Share by Application (2024-2034)
Table 50. Antiretroviral Agent Price by Application (2018-2024) & (US$/Unit)
Table 51. Global Antiretroviral Agent Price Forecast by Application (2024-2034) & (US$/Unit)
Table 52. North America Antiretroviral Agent Revenue by Company (2018-2024) & (US$ Million)
Table 53. North America Antiretroviral Agent Sales Quantity by Company (2018-2024) & (K Units)
Table 54. North America Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 55. North America Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 56. North America Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 57. North America Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 59. North America Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 60. North America Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 61. North America Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 63. North America Antiretroviral Agent Revenue by Country (2018-2024) & (US$ Million)
Table 64. North America Antiretroviral Agent Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America Antiretroviral Agent Sales Quantity by Country (2018-2024) & (K Units)
Table 66. North America Antiretroviral Agent Sales Quantity by Country (2024-2034) & (K Units)
Table 67. Europe Antiretroviral Agent Sales Quantity by Company (2018-2024) & (K Units)
Table 68. Europe Antiretroviral Agent Revenue by Company (2018-2024) & (US$ Million)
Table 69. Europe Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 70. Europe Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 71. Europe Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 72. Europe Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 74. Europe Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 75. Europe Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 76. Europe Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 78. Europe Antiretroviral Agent Revenue by Country (2018-2024) & (US$ Million)
Table 79. Europe Antiretroviral Agent Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe Antiretroviral Agent Sales Quantity by Country (2018-2024) & (K Units)
Table 81. Europe Antiretroviral Agent Sales Quantity by Country (2024-2034) & (K Units)
Table 82. China Antiretroviral Agent Sales Quantity by Company (2018-2024) & (K Units)
Table 83. China Antiretroviral Agent Revenue by Company (2018-2024) & (US$ Million)
Table 84. China Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 85. China Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 86. China Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 87. China Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 88. China Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 89. China Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 90. China Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 91. China Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC Antiretroviral Agent Sales Quantity by Company (2018-2024) & (K Units)
Table 93. APAC Antiretroviral Agent Revenue by Company (2018-2024) & (US$ Million)
Table 94. APAC Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 95. APAC Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 96. APAC Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 97. APAC Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 99. APAC Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 100. APAC Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 101. APAC Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 103. APAC Antiretroviral Agent Revenue by Region (2018-2024) & (US$ Million)
Table 104. APAC Antiretroviral Agent Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC Antiretroviral Agent Sales Quantity by Region (2018-2024) & (K Units)
Table 106. APAC Antiretroviral Agent Sales Quantity by Region (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Company (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Company (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Type (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Type (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Type (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Application (2018-2024) & (K Units)
Table 114. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Application (2024-2034) & (K Units)
Table 115. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Application (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Country (2018-2024) & (US$ Million)
Table 119. Middle East, Africa and Latin America Antiretroviral Agent Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Country (2018-2024) & (K Units)
Table 121. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity by Country (2024-2034) & (K Units)
Table 122. ViiV Healthcare Company Information
Table 123. ViiV Healthcare Description and Overview
Table 124. ViiV Healthcare Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 125. ViiV Healthcare Antiretroviral Agent Product and Services
Table 126. ViiV Healthcare Antiretroviral Agent SWOT Analysis
Table 127. ViiV Healthcare Recent Developments
Table 128. Gilead Sciences Company Information
Table 129. Gilead Sciences Description and Overview
Table 130. Gilead Sciences Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 131. Gilead Sciences Antiretroviral Agent Product and Services
Table 132. Gilead Sciences Antiretroviral Agent SWOT Analysis
Table 133. Gilead Sciences Recent Developments
Table 134. GlaxoSmithKline Company Information
Table 135. GlaxoSmithKline Description and Overview
Table 136. GlaxoSmithKline Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 137. GlaxoSmithKline Antiretroviral Agent Product and Services
Table 138. GlaxoSmithKline Antiretroviral Agent SWOT Analysis
Table 139. GlaxoSmithKline Recent Developments
Table 140. Merck Sharp and Dohme Company Information
Table 141. Merck Sharp and Dohme Description and Overview
Table 142. Merck Sharp and Dohme Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 143. Merck Sharp and Dohme Antiretroviral Agent Product and Services
Table 144. Merck Sharp and Dohme Antiretroviral Agent SWOT Analysis
Table 145. Merck Sharp and Dohme Recent Developments
Table 146. Bristol-Myers Squibb Company Information
Table 147. Bristol-Myers Squibb Description and Overview
Table 148. Bristol-Myers Squibb Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 149. Bristol-Myers Squibb Antiretroviral Agent Product and Services
Table 150. Bristol-Myers Squibb Antiretroviral Agent SWOT Analysis
Table 151. Bristol-Myers Squibb Recent Developments
Table 152. Janssen Pharmaceuticals Company Information
Table 153. Janssen Pharmaceuticals Description and Overview
Table 154. Janssen Pharmaceuticals Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 155. Janssen Pharmaceuticals Antiretroviral Agent Product and Services
Table 156. Janssen Pharmaceuticals Antiretroviral Agent SWOT Analysis
Table 157. Janssen Pharmaceuticals Recent Developments
Table 158. Pfizer Company Information
Table 159. Pfizer Description and Overview
Table 160. Pfizer Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 161. Pfizer Antiretroviral Agent Product and Services
Table 162. Pfizer Antiretroviral Agent SWOT Analysis
Table 163. Pfizer Recent Developments
Table 164. Boehringer Ingelheim Company Information
Table 165. Boehringer Ingelheim Description and Overview
Table 166. Boehringer Ingelheim Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 167. Boehringer Ingelheim Antiretroviral Agent Product and Services
Table 168. Boehringer Ingelheim Antiretroviral Agent SWOT Analysis
Table 169. Boehringer Ingelheim Recent Developments
Table 170. AbbVie Company Information
Table 171. AbbVie Description and Overview
Table 172. AbbVie Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 173. AbbVie Antiretroviral Agent Product and Services
Table 174. AbbVie Antiretroviral Agent SWOT Analysis
Table 175. AbbVie Recent Developments
Table 176. Genentech Company Information
Table 177. Genentech Description and Overview
Table 178. Genentech Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 179. Genentech Antiretroviral Agent Product and Services
Table 180. Genentech Antiretroviral Agent SWOT Analysis
Table 181. Genentech Recent Developments
Table 182. Mylan Company Information
Table 183. Mylan Description and Overview
Table 184. Mylan Antiretroviral Agent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 185. Mylan Antiretroviral Agent Product and Services
Table 186. Mylan Recent Developments
Table 187. Key Raw Materials Lists
Table 188. Raw Materials Key Suppliers Lists
Table 189. Antiretroviral Agent Distributors List
Table 190. Antiretroviral Agent Customers List
Table 191. Antiretroviral Agent Market Trends
Table 192. Antiretroviral Agent Market Drivers
Table 193. Antiretroviral Agent Market Challenges
Table 194. Antiretroviral Agent Market Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Antiretroviral Agent Product Picture
Figure 2. Global Antiretroviral Agent Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Antiretroviral Agent Market Share by Type in 2022 & 2034
Figure 4. Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 5. Protease Inhibitors Product Picture
Figure 6. HIV Integrase Strand Transfer Inhibitors Product Picture
Figure 7. Non-Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 8. Entry Inhibitors—CCR5 Co-Receptor Antagonist Product Picture
Figure 9. Fusion Inhibitors Product Picture
Figure 10. Others Product Picture
Figure 11. Global Antiretroviral Agent Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 12. Global Antiretroviral Agent Market Share by Application in 2022 & 2034
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Others
Figure 17. Antiretroviral Agent Report Years Considered
Figure 18. Global Antiretroviral Agent Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Antiretroviral Agent Revenue 2018-2034 (US$ Million)
Figure 20. Global Antiretroviral Agent Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 21. Global Antiretroviral Agent Sales Quantity 2018-2034 (K Units)
Figure 22. Global Antiretroviral Agent Sales Quantity Market Share by Region (2018-2024)
Figure 23. Global Antiretroviral Agent Sales Quantity Market Share by Region (2024-2034)
Figure 24. North America Antiretroviral Agent Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. North America Antiretroviral Agent Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Europe Antiretroviral Agent Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Europe Antiretroviral Agent Revenue YoY (2018-2034) & (US$ Million)
Figure 28. China Antiretroviral Agent Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. China Antiretroviral Agent Revenue YoY (2018-2034) & (US$ Million)
Figure 30. APAC Antiretroviral Agent Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. APAC Antiretroviral Agent Revenue YoY (2018-2034) & (US$ Million)
Figure 32. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity YoY (2018-2034) & (K Units)
Figure 33. Middle East, Africa and Latin America Antiretroviral Agent Revenue YoY (2018-2034) & (US$ Million)
Figure 34. The Top 10 and Top 5 Players Market Share by Antiretroviral Agent Sales Quantity in 2022
Figure 35. The Top 10 and Top 5 Players Market Share by Antiretroviral Agent Revenue in 2022
Figure 36. Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 37. Global Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 38. Global Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 39. Global Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 40. Global Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 41. North America Antiretroviral Agent Revenue Market Share by Company in 2022
Figure 42. North America Antiretroviral Agent Sales Quantity Market Share by Company in 2022
Figure 43. North America Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 44. North America Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 45. North America Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 46. North America Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 47. North America Antiretroviral Agent Revenue Share by Country (2018-2034)
Figure 48. North America Antiretroviral Agent Sales Quantity Share by Country (2018-2034)
Figure 49. United States Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 50. Canada Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 51. Europe Antiretroviral Agent Sales Quantity Market Share by Company in 2022
Figure 52. Europe Antiretroviral Agent Revenue Market Share by Company in 2022
Figure 53. Europe Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 54. Europe Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 55. Europe Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 56. Europe Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 57. Europe Antiretroviral Agent Revenue Share by Country (2018-2034)
Figure 58. Europe Antiretroviral Agent Sales Quantity Share by Country (2018-2034)
Figure 59. Germany Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 60. France Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 61. U.K. Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 62. Italy Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 63. Russia Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 64. China Antiretroviral Agent Sales Quantity Market Share by Company in 2022
Figure 65. China Antiretroviral Agent Revenue Market Share by Company in 2022
Figure 66. China Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 67. China Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 68. China Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 69. China Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 70. APAC Antiretroviral Agent Sales Quantity Market Share by Company in 2022
Figure 71. APAC Antiretroviral Agent Revenue Market Share by Company in 2022
Figure 72. APAC Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 73. APAC Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 74. APAC Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 75. APAC Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 76. APAC Antiretroviral Agent Revenue Share by Region (2018-2034)
Figure 77. APAC Antiretroviral Agent Sales Quantity Share by Region (2018-2034)
Figure 78. Japan Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 79. South Korea Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 80. China Taiwan Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 81. Southeast Asia Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 82. India Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 83. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity Market Share by Company in 2022
Figure 84. Middle East, Africa and Latin America Antiretroviral Agent Revenue Market Share by Company in 2022
Figure 85. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Antiretroviral Agent Revenue Market Share by Type (2018-2034)
Figure 87. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Antiretroviral Agent Revenue Market Share by Application (2018-2034)
Figure 89. Middle East, Africa and Latin America Antiretroviral Agent Sales Quantity Share by Country (2018-2034)
Figure 90. Middle East, Africa and Latin America Antiretroviral Agent Revenue Share by Country (2018-2034)
Figure 91. Brazil Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 92. Mexico Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 93. Turkey Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 94. Israel Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 95. GCC Countries Antiretroviral Agent Revenue (2018-2034) & (US$ Million)
Figure 96. Antiretroviral Agent Value Chain
Figure 97. Antiretroviral Agent Production Process
Figure 98. Channels of Distribution (Direct Vs Distribution)
Figure 99. Distributors Profiles
Figure 100. Bottom-up and Top-down Approaches for This Report
Figure 101. Data Triangulation
Figure 102. Key Executives Interviewed